MSLN and ovarian serous adenocarcinoma: [24] However, concordance of KRAS mutation and mesothelin expression have not been observed in mesothelioma and high grade serous ovarian cancers where robust mesothelin expression is nearly universal [8, 17] and KRAS mutation quite rare.